Heartseed, a Tokyo, Japan-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), raised 2.8 Billion-yen (approx. $26m) in Series B funding.
Backers in this round, which brought total financial raised to date to 3.8 Billion yen (approx. $35M) since it was founded in 2015, included SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Capital, and existing investor Astellas Venture Management LLC.
The company will use the funds to initiate Phase 1/2 clinical trial for its lead pipeline HS-001 for HF with reduced Ejection Fraction (HFrEF) in late 2020, and support an investigator-initiated clinical trial for Dilated Cardiomyopathy led by Keio University, which is expected to be initiated in the first half of 2020.
Led by Prof. Keiichi Fukuda, co-founder and CEO, Professor at the Department of Cardiology, Keio University, Tokyo, Heartseed develops and commercializes cardiac regenerative medicine leveraging original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purification, cell delivery and iPSC production.
FinSMEs
22/11/2019